Merrill reiterates New River at buy

New River Pharmaceuticals Inc. was reiterated at buy with a $56 price objective by Merrill Lynch analyst David Munno, who predicted NRP104 will launch shortly after October 2006. Additionally, New River's Adderall XR for the treatment of Attention Deficit-Hyperactivity Disorder gained one point of market share in the third quarter, while the market for ADHD drugs expanded 4% over last year. Shares of the Radford, Va.-based biotechnology company were up $0.79, or 1.67%, at $48.01 on volume of 29,598 shares versus a three-month running average of 87,196 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.